Core Viewpoint - The exclusive distribution rights of *ST Suwu's subsidiary, Datou Medical, are set to be revoked by Aimeike, which could significantly impact *ST Suwu's medical aesthetics business revenue and profits in the second half of 2025 [5][6][15]. Group 1: Company Actions and Implications - Aimeike's subsidiary, REGEN Biotech, Inc., sent a termination notice to Datou Medical on July 18, 2023, to revoke its exclusive distribution rights for the AestheFill product in mainland China [5][9]. - If the termination is finalized, Datou Medical will be unable to sell AestheFill products, leading to a substantial decrease in revenue and profit for *ST Suwu's medical aesthetics segment [6][15]. - In 2024, AestheFill contributed 326 million yuan to *ST Suwu's total revenue, accounting for 20.42%, and in Q1 2025, it generated 113 million yuan, representing 35.55% of the company's revenue [6][16][17]. Group 2: Legal and Regulatory Context - *ST Suwu has denied any breach of contract and plans to take legal action to protect its rights [6][20]. - The termination notice cites that Datou Medical allegedly transferred its exclusive distribution business to its parent company, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., which violates the agreement [21][22]. - Recent regulatory issues have plagued *ST Suwu, including administrative penalties for violations of securities laws, which could lead to significant consequences, including potential delisting [24][26].